BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30781783)

  • 21. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
    Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
    Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin.
    Wang H; Wu Q; Zhang Y; Zhang HN; Wang YB; Wang W
    Cell Mol Biol Lett; 2017; 22():22. PubMed ID: 29118814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
    Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H
    Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Genet Test Mol Biomarkers; 2018 Jun; 22(6):333-342. PubMed ID: 29812958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/β-catenin signaling in non-small-cell lung cancer.
    Yang Y; Sun Y; Wu Y; Tang D; Ding X; Xu W; Su B; Gao W
    Mol Carcinog; 2018 Jul; 57(7):842-853. PubMed ID: 29566281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells.
    Wang H; Zhang Y; Wu Q; Wang YB; Wang W
    Oncol Rep; 2018 Jan; 39(1):247-254. PubMed ID: 29138833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1.
    Jin X; Yu Y; Zou Q; Wang M; Cui Y; Xie J; Wang Z
    J Cell Biochem; 2019 Apr; 120(4):5880-5888. PubMed ID: 30317672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
    Cheng L; Gou L; Wei T; Zhang J
    Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
    Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
    J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roles of miR-200 family members in lung cancer: more than tumor suppressors.
    Liu C; Hu W; Li LL; Wang YX; Zhou Q; Zhang F; Song-Yang YY; Zhu W; Sun CC; Li DJ
    Future Oncol; 2018 Nov; 14(27):2875-2886. PubMed ID: 30208739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation.
    Camerlingo R; Miceli R; Marra L; Rea G; D'Agnano I; Nardella M; Montella R; Morabito A; Normanno N; Tirino V; Rocco G
    PLoS One; 2019; 14(7):e0219597. PubMed ID: 31344049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
    Kumar M; Jaiswal RK; Prasad R; Yadav SS; Kumar A; Yadava PK; Singh RP
    Life Sci; 2021 Mar; 269():118994. PubMed ID: 33417952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiRNA-200b represses transforming growth factor-β1-induced EMT and fibronectin expression in kidney proximal tubular cells.
    Tang O; Chen XM; Shen S; Hahn M; Pollock CA
    Am J Physiol Renal Physiol; 2013 May; 304(10):F1266-73. PubMed ID: 23408168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
    Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
    Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
    Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.